Novo Nordisk Shares Fall as Wegovy Pill Sales Miss Estimates

Shares of Novo Nordisk (NOVOb) fell on Wednesday after the Danish pharmaceutical company's second-quarter earnings report presented a mixed picture, overshadowing an improved financial outlook for the full year. The stock traded down 3.8% to DKK 296 in Copenhagen after investors reacted to disappointing sales for the new pill version of its blockbuster weight-loss drug Wegovy and fresh concerns about its long-term product pipeline.

A Mixed Earnings Report

In its Q2 2026 earnings, released a day ahead of schedule, Novo Nordisk reported that the newly launched oral version of Wegovy generated DKK 3.22 billion in revenue. This figure fell just short of the DKK 3.27 billion analysts had anticipated, a key point of concern for the market.

While adjusted operating profit rose 11% on a constant-exchange-rate basis to DKK 33.4 billion, analysts noted the beat was aided by temporary factors, including rebate adjustments. Despite the mixed results, Novo Nordisk raised its full-year guidance, now expecting adjusted sales and operating profit to land between 0% and -6% at constant exchange rates, an improvement from its prior forecast of -12% to -4%.

Investor Concerns Outweigh Guidance

The upgraded forecast was not enough to assuage investor concerns. According to BMO Capital Markets, the market's negative reaction was driven by the surprise revenue miss for the Wegovy pill and lower-than-expected U.S. sales for the injectable version of the product.

Ad

Adding to the uncertainty were recent pipeline developments. The company disclosed a disappointing clinical result for its next-generation weight-loss drug, CagriSema, following the late-July ZEUS trial failure. This setback has reinforced investor questions about the company’s ability to develop new blockbuster treatments.

Competitive Pressures and Outlook

Novo Nordisk operates in an increasingly competitive market for GLP-1 drugs, with U.S. rival Eli Lilly posing a significant challenge in a market that some analysts project could exceed $100 billion in annual revenue by 2030. The company itself flagged an expected sales decline in its U.S. operations, citing prescription trends, intensifying competition, and reduced Medicaid coverage for obesity medicines.

Reflecting the cautious sentiment, analysts at Jefferies maintained a Hold rating on the stock with a price target of DKK 285. The combination of the Wegovy pill miss, pipeline setbacks, and questions about profit quality proved more significant to investors than the improved annual guidance.